PFS Not Improved With Atezolizumab/Cobimetinib Combo in Phase III IMspire170 Trial

Source: Targeted Oncology, July 2019

The phase III IMspire170 trial (NCT03273153) failed to meet its primary endpoint according to topline results from the study. The combination of atezolizumab (Tecentriq) and cobimetinib (Cotellic) did not improve progression-free survival compared with pembrolizumab (Keytruda) in patients with previously untreated BRAF V600 wild-type melanoma.

The safety profile observed with the combination regimen was consistent with the known safety profiles of each agent alone, wrote Exelixis, the manufacturer of cobimetinib, in a statement to the United States Securities and Exchange Commission.

Genentech, which manufactures atezolizumab and is the sponsor of the trial, announced that it will present the findings at an upcoming medical meeting.